---
title: "Exelixis Director Jack L Wyszomierski Sells 99,574 Shares"
description: "Jack L Wyszomierski, a Director at Exelixis, sold 99,574 shares of Common Stock on February 18, 2026, for a total of $4,382,251 at a weighted average price of $44.01 per share. After the sale, he reta"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276499134.md"
published_at: "2026-02-21T01:40:01.000Z"
---

# Exelixis Director Jack L Wyszomierski Sells 99,574 Shares

> Jack L Wyszomierski, a Director at Exelixis, sold 99,574 shares of Common Stock on February 18, 2026, for a total of $4,382,251 at a weighted average price of $44.01 per share. After the sale, he retains ownership of 279,942 shares, including 9,812 shares pending vesting of restricted stock units. This transaction was reported in SEC Form 4.

Jack L Wyszomierski, serving as a Director at Exelixis, sold 99,574 shares of Common Stock on February 18, 2026, at a weighted average price of $44.01 per share, totaling $4,382,251. Following this transaction, Wyszomierski directly owns 279,942 shares of Exelixis, including 9,812 shares to be issued upon vesting of restricted stock units.

Reporter Name

Wyszomierski Jack L

Relationship

Director

Type

Sell

Amount

$4,382,251

SEC Filing

Form 4

SEC Filing: EXELIXIS, INC. \[ EXEL \] - Form 4 - Feb. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US - Health Care Select Sector SPDR](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSA Capital Partners LLP Raises Stock Holdings in Merck & Co., Inc. $MRK | GSA Capital Partners LLP increased its stake in Merck & Co., Inc. by 107.8% in Q3, owning 24,809 shares valued at $2.08  | [Link](https://longbridge.com/en/news/276119315.md) |
| Lunai Bioworks Inc. SEC 10-Q Report | Lunai Bioworks Inc. has released its latest Form 10-Q report, indicating improved financial performance with total opera | [Link](https://longbridge.com/en/news/276164384.md) |
| The Ensign Group (NASDAQ:ENSG) Director Pison Marivic Uychiat Sells 67 Shares | The Ensign Group (NASDAQ:ENSG) Director Pison Marivic Uychiat sold 67 shares at $204.92 each, totaling $13,729.64, resul | [Link](https://longbridge.com/en/news/276498475.md) |
| Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Skandinaviska Enskilda Banken AB publ | Skandinaviska Enskilda Banken AB publ increased its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 361.6% in Q | [Link](https://longbridge.com/en/news/276321074.md) |
| Cencora to Receive $1.25B Cash, $2.25B Equity for MWI in $3.5B Deal; Retains 34.3% Stake | Cencora has announced a merger agreement to combine MWI Animal Health with Covetrus, valuing MWI at $3.5 billion. Cencor | [Link](https://longbridge.com/en/news/276228894.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.